DRTS and DRTSW Related Headlines
Go Back- Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Alpha Tau to Participate in May Investor Conferences
- Alpha Tau reports interim brain cancer trial results in 3 patients
- Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Ob
- Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
- Alpha Tau completes enrollment in pivotal skin cancer trial
- Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
- Alpha Tau to present head and neck cancer study at AHNS conference
- Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembro
- Alpha Tau reports 100% disease control in pancreatic cancer trials
- Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
- Alpha Tau abstract accepted at ASCO annual meeting for pancreatic cancer data
- Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
- FDA approves Alpha Tau trial expansion for pancreatic cancer treatment
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
- Alpha Tau to Participate in December Investor Conferences
- Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
- Alpha Tau to Participate in Five September Investor Conferences
- Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
DRTS and DRTSW Related Press Releases
Go Back- Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Alpha Tau to Participate in May Investor Conferences
- Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Ob
- Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
- Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
- Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembro
- Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
- Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
- Alpha Tau to Participate in December Investor Conferences
- Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
- Alpha Tau to Participate in Five September Investor Conferences
- Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
